
NUTX Stock Forecast & Price Target
NUTX Analyst Ratings
Bulls say
Nutex Health is viewed favorably because the recent Fifth Circuit TMA III ruling and lower IDR fees should reduce “ghost rate” distortions, cut arbitration friction, and accelerate collections, while management already sees 80%+ collections and more than 85% win rates on disputed claims. The core business also looks attractive on unit economics: each hospital averages about $35M of revenue and roughly $10M of EBITDA, with high-40s to low-50s gross margins, low-30s EBITDA margins, and breakeven around 15 visits per day. Growth is further supported by a visible de novo pipeline of 10+ openings through 2028, expected low-teens 2027 revenue growth, strong cash generation of $248M in operating cash flow in 2025 and $109.7M in 1H26, and a net cash balance of $205.2M versus $39.7M of debt at June 30.
Bears say
Nutex Health is exposed to a fragile operating model where physician and nursing shortages, reimbursement cuts, and intensifying competition from retail clinics, telemedicine, and virtual visits can suppress patient volumes and strain revenue growth. Its dependence on out-of-network reimbursement through the federal IDR process creates significant earnings volatility, while adverse CMS rulemaking, litigation, or tighter regulatory scrutiny could compress award levels, reduce win rates, and limit the share of claims eligible for arbitration. Financially, the company’s results are hard to forecast because profitability is tied to lumpy arbitration-derived reimbursement, and execution or financing setbacks in sale-leaseback activity could weaken the balance sheet and slow capital recycling.
This aggregate rating is based on analysts' research of Nutex Health Inc and is not a guaranteed prediction by Public.com or investment advice.
NUTX Analyst Forecast & Price Prediction
Start investing in NUTX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Nutex Health Inc (NUTX) Forecast
NUTX Analyst Forecast & Price Prediction
Start investing in NUTX
Order type
Buy in
Order amount
Est. shares
0 shares